Clinical trials: Type Two Diabetes Mellitus
Diabetes
Glycemic Response to Oral Nutrition Supplements
This will be a randomized, cross-over study of two oral nutrition supplements in individuals with Type 2 Diabetes.
- Trial name
- NCT02612675
- Testing
- ONS
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
This trial is conducted in Europe, North America and the United States of America. The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.
- Trial name
- DUAL™ VI (NCT02298192)
- Testing
- insulin degludec/liraglutide
- Where
- 84 sites in United States, Austria and 7 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2…
- Trial name
- NCT00560417
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glulisine in Diabetes Mellitus, Type 2
Primary objective: The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change…
- Trial name
- GINGER (NCT00174668)
- Testing
- Insulin Glulisine, Insulin Therapy, Insulin Glargine
- Where
- 15 sites in Australia, Belgium and 13 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination
This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea…
- Trial name
- NCT00044668
- Testing
- AC2993
- Where
- 3 sites in Hungary
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
T2DM (Type 2 Diabetes Mellitus)
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition
- Trial name
- NCT04706286
- Testing
- CKD-501, D759, D150, CKD-393 0.5/100/1000 mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01843127
- Testing
- Ranolazine, Exenatide
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble Insulin Analogue Combination [SIAC], insulin degludec/insulin aspart) formulations with each other and with biphasic insulin aspart 30…
- Trial name
- NCT00613951
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart, metformin
- Where
- 31 sites in Finland, France and 3 more
- Volunteers
- 182 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06792968
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Diabetes Mellitus, Type 2
A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the results from two methods used to determine the renal threshold for glucose excretion (defined as the lowest plasma glucose concentration at which appreciable amounts of glucose appear…
- Trial name
- NCT01273558
- Testing
- Canagliflozin
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension, Diabetes Mellitus, Type 2
A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.
- Trial name
- NCT06063109
- Testing
- THP-00101 (Dapagliflozin) 10mg, THP-00102 (Telmisartan) 80mg
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- THPharm Corp.
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124495
- Testing
- Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Obesity, Microalbuminuria
Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors
Primary objective: To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.
- Conditions
- Obesity, Microalbuminuria, Diabetes Mellitus, Type 2, Dyslipidemia
- Trial name
- RIALTO (NCT00458081)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Sanofi
Diabetes Mellitus
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
- Trial name
- NCT00287066
- Testing
- Inhaled Human Insulin, Regular Human Insulin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain, Diabetic Neuropathies
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and…
- Trial name
- NCT00375960
- Testing
- V3381
- Where
- 6 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Vernalis (R&D) Ltd
Diabetes, Diabetes Mellitus, Type 2
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on…
- Trial name
- NCT01068652
- Testing
- insulin detemir, insulin aspart, biphasic insulin aspart 30
- Where
- 19 sites in Algeria, Egypt and 3 more
- Volunteers
- 403 people
- Sponsor
- Novo Nordisk A/S
Hypertension
Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
- Trial name
- NCT00160225
- Testing
- Daglutril
- Where
- Italy
- Sponsor
- Solvay Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in…
- Trial name
- NCT00611884
- Testing
- insulin glargine, insulin degludec, metformin
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
- Trial name
- NCT00853151
- Testing
- LY2428757, TT223
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company